Valneva is developing vaccines against infections due to human metapneumovirus (hMPV), Zika virus and Yellow fever virus. The vaccines are developed using Valneva's EB66® cell line, which is based on a duck embryonic stem cell substrate platform. The vaccine for yellow fever is a second generation vaccine. Preclinical development for Zika virus and Yellow fever, and early research for hMPV vaccine candidates is underway in France.
VLA 1601, a highly purified inactivated vaccine, being developed in collaboration with Emergent BioSolutions for the prevention of Zika virus infections, has entered clinical development [see AdisInsight drug profile 800051396].
VLA 1553, a monovalent, live attenuated chikungunya vaccine candidate has entered clinical development [see Adis Insight profile 800051500].
Valneva is looking for partners to advance its pipeline vaccine candidates, which are developed using its propriety technologies.
As at April 2020, no recent reports of development had been identified for preclinical development in Yellow-fever (Prevention) in France, research development in Metapneumovirus-infections (Prevention) in France.
Key Development Milestones
Zika virus vaccine is undergoing preclinical proof-of-concept studies. In July 2016, Valneva generated Zika vaccine candidate, based on the IXIARO® platform, and the candidate demonstrated excellent purity and had a biological, chemical and physical profile comparable to the commercially available Japanese enchephalitis vaccine [see AdisInsight drug profile 800019333]   .
Valneva, in July 2016, secured a €25 million loan facility from European Investment Bank. Valneva plans to use the proceeds to support the research and development of vaccines including its Zika vaccine candidate  .